Income Statement

C4 THERAPEUTICS, INC.

CCCC
Annual
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY
Revenue
35.95 35.58 20.76 31.10 - -
Cost of Revenue
- - - - - -
Gross Profit
35.95 35.58 20.76 31.10 - -
Operating Expenses
151.17 155.20 159.79 160.63 127.92 93.64
Research & Development
104.24 110.64 117.71 117.84 94.67 78.44
Selling, General & Administrative
36.20 42.12 42.08 42.79 33.25 15.20
Other Operating Expenses
- - - - - -
Operating Income
-115.22 -119.61 -139.03 -129.53 -127.92 -93.64
Non-Operating Income
10.35 14.43 7.82 1.36 -1.76 -6.51
Interest Income
- - - - - -
Interest Expense
- - - - - -
Other Non-Op Income / Expense
- - - - - -
Income Before Tax
-104.87 -105.19 -131.21 - -83.89 -66.96
Income Tax Expense
0.12 0.13 1.28 - 0.00 -0.63
Non-Controlling Interest
- - - - - -
Net Income
-104.99 -105.32 -132.49 -128.18 -83.89 -66.34
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY
Depreciation & Amortization
- - - - - -
EBITDA
-113.26 -117.80 -137.15 -127.86 -126.43 -92.03
Earnings Per Share (Basic)
-1.27 -1.52 -2.67 -2.62 -1.82 -5.83
Diluted EPS
-1.27 -1.52 -2.67 -2.62 - -
Weighted Average Shares
82.89 69.37 49.64 48.86 - -
Diluted Weighted Avg Shares
82.89 69.37 49.64 48.86 - -
Comprehensive Income
-105.00 -105.14 -128.48 -131.54 -84.68 -66.32